Andrew Packman to lead PwC’s UK pharmaceutical and life sciences business

PwC has announced the appointment of Andrew Packman as head of the firm’s UK pharmaceutical and life sciences business, succeeding Andy Kemp.

Andrew will lead PwC’s work in the UK pharmaceutical and life sciences market. He takes up the role immediately.

Commenting on his appointment, Andrew Packman, UK pharmaceutical and life sciences leader, said:

“I am delighted with my new appointment. As a firm, we are committing further significant investment to the UK pharmaceutical group and building on the considerable strengths we already possess.”

Andrew has been with the firm for over 25 years and a partner for the last 14 years. For much of his time at PwC, Andrew has specialised in the Pharmaceutical and Life Sciences industry and has led the firm’s tax practice in the industry for some years. This has included working closely with trade bodies and Government on the development of policy on R&D tax reliefs and more recently on the Patent Box.